ES2605152T3 - Derivados de pirazolquinolinona, su preparación y su uso terapéutico - Google Patents

Derivados de pirazolquinolinona, su preparación y su uso terapéutico Download PDF

Info

Publication number
ES2605152T3
ES2605152T3 ES12761636.5T ES12761636T ES2605152T3 ES 2605152 T3 ES2605152 T3 ES 2605152T3 ES 12761636 T ES12761636 T ES 12761636T ES 2605152 T3 ES2605152 T3 ES 2605152T3
Authority
ES
Spain
Prior art keywords
nra
aryl
alkyl
nrarb
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12761636.5T
Other languages
English (en)
Inventor
Alexandre Benazet
Olivier Duclos
Nathalie Guillo
Gilbert Lassalle
Karim Macary
Valérie VIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of ES2605152T3 publication Critical patent/ES2605152T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/62—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Medicamento, caracterizado porque comprende un compuesto de fórmula (I):**Fórmula** en la que: R1 representa: * -alquilo (C1-C4) * -haloalquilo (C1-C4) R2 representa: * un grupo: * un grupo:**Fórmula** * un grupo:**Fórmula** -A -X R3 representa: * -H * halógeno * -alquilo (C1-C6) * un grupo ciano * -CO2H * -CONH2 A representa: * un grupo arilo o heteroarilo X está ausente o representa: * halógeno * un grupo ciano * un grupo oxo * -(CH2)nOH * -haloalquilo (C1-C6) * -alquilo (C1-C6) * -alcoxi (C1-C6) 5 * -(CH2)n-arilo * -CHOH-arilo * heterociclo * heteroarilo * -alquil (C1-C6)-heterociclo 10 * -alquil (C1-C6)-heteroarilo * -alquil (C1-C6)-COORa * -alquil (C1-C6)-NRaRb * -heteroaril-(CH2)n-NRaRb * -(CH2)n-NRa-C(O)-Rb 15 * -NRaRb * -NRa-(CH2)n-O-Rb * -NRa-heterociclo * -NRa-arilo * -NRa-C(O)-(CH2)n-NRaRb 20 * -NRa-C(O)-arilo * -NRaC(O)-alquilo (C1-C6) * -NRa-C(O)-alquil (C1-C6)-arilo * -NRa-C(O)-(CH2)n-O-Rb * -NRa-SO2-(CH2)n-arilo * -NRa-SO2-(CH2)n-NRaRb * -NRa-SO2-Rb * -NRa-SO2-aril-O-arilo * -NRa-SO2-aril-(CH2)n-NRb-C(O)-Rb * -COORa * -CONRaRb * -C(O)-NRa-(CH2)n-O-Rb * -C(O)-NRa-aril-C(O)-NRaRb * -C(O)-NRa-(CH2)n-NRaRb * -C(O)-NRa-(CH2)n-heteroarilo * -O-(CH2)n-NRaRb * -O-heterociclo * -CO-heterociclo * -CO-heteroarilo * -SO2NRaRb * -SO2-heterociclo Ra y Rb representan, independientemente: * -H * -alquilo (C1-C6) n representa 0, 1, 2 o 3 o una sal de adición de este compuesto con un ácido farmacéuticamente aceptable.
ES12761636.5T 2011-09-26 2012-09-24 Derivados de pirazolquinolinona, su preparación y su uso terapéutico Active ES2605152T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306217.8A EP2573073B1 (en) 2011-09-26 2011-09-26 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
EP11306217 2011-09-26
PCT/EP2012/068786 WO2013045400A1 (en) 2011-09-26 2012-09-24 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof

Publications (1)

Publication Number Publication Date
ES2605152T3 true ES2605152T3 (es) 2017-03-13

Family

ID=46880738

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11306217.8T Active ES2527188T3 (es) 2011-09-26 2011-09-26 Derivados de pirazolquinolinona, su preparación y su uso terapéutico
ES12761636.5T Active ES2605152T3 (es) 2011-09-26 2012-09-24 Derivados de pirazolquinolinona, su preparación y su uso terapéutico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES11306217.8T Active ES2527188T3 (es) 2011-09-26 2011-09-26 Derivados de pirazolquinolinona, su preparación y su uso terapéutico

Country Status (22)

Country Link
EP (2) EP2573073B1 (es)
JP (1) JP6073328B2 (es)
KR (1) KR20140082743A (es)
CN (1) CN103958479B (es)
AR (1) AR088000A1 (es)
AU (1) AU2012314620B2 (es)
BR (1) BR112014007193A2 (es)
CA (1) CA2847921A1 (es)
CY (1) CY1115945T1 (es)
DK (1) DK2573073T3 (es)
ES (2) ES2527188T3 (es)
HR (1) HRP20150024T1 (es)
IL (1) IL231386A (es)
MX (1) MX2014003675A (es)
PL (1) PL2573073T3 (es)
PT (1) PT2573073E (es)
RU (1) RU2621037C2 (es)
SG (1) SG11201400403SA (es)
SI (1) SI2573073T1 (es)
TW (1) TWI527815B (es)
UY (1) UY34350A (es)
WO (1) WO2013045400A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
CA2907532A1 (en) 2013-03-25 2014-10-02 Sanofi Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)
EP2982675B1 (en) * 2013-04-05 2017-08-16 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
TW201439091A (zh) 2013-04-05 2014-10-16 Eisai R&D Man Co Ltd 吡啶基吡唑并喹啉化合物
GB201406486D0 (en) 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
GB201516616D0 (en) * 2015-09-18 2015-11-04 Redx Pharma Plc Antibacterial compounds
SG11201801856XA (en) * 2015-09-18 2018-04-27 Kaken Pharmaceutical Co Ltd Biaryl derivative and medicine containing same
CN105198888B (zh) * 2015-10-01 2018-03-06 湘潭大学 2,3a‑二取代‑3H–吡唑并[1,5‑a]吲哚‑4(3aH)‑酮衍生物及其合成方法
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
JP6469272B2 (ja) * 2017-03-01 2019-02-13 科研製薬株式会社 ビアリール誘導体又はその塩からなる医薬
CN108721621B (zh) * 2017-04-14 2022-03-01 中国科学院上海高等研究院 抑制肝纤维化的小分子化合物及应用
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
RU2656225C1 (ru) * 2017-06-22 2018-06-04 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ получения производных пирроло[2,1-a]изохинолинов
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
PE20210160A1 (es) 2018-04-25 2021-01-26 Innate Tumor Immunity Inc Moduladores de nlrp3
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
CA3126334A1 (en) 2019-01-11 2020-07-16 Shionogi & Co., Ltd. Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity
CN110845478B (zh) * 2019-11-25 2022-07-08 南通大学 含1-取代吡啶基-3-三氟甲基吡唑单元的吡唑甲酰肟衍生物的制备和用途
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
US12600717B2 (en) 2021-07-14 2026-04-14 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167240B (es) * 1972-06-30 1975-09-27
US3880855A (en) * 1973-04-16 1975-04-29 Bristol Myers Co 5,6-DIHYDRO-11-H-pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines
TW200508233A (en) * 2003-05-29 2005-03-01 Millennium Pharm Inc Chk-1 inhibitors
DE602004014969D1 (de) * 2003-11-21 2008-08-21 Novartis Ag 1h-imidazochinolinderivate als proteinkinaseinhibitoren
EP1828180A4 (en) * 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
JP2008526791A (ja) * 2005-01-07 2008-07-24 アルパイダ アーゲー 選択されたベンゾフラン誘導体
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
RS54834B1 (sr) * 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
DE102010048374A1 (de) * 2010-10-13 2012-04-19 Merck Patent Gmbh Pyrrolidinone als MetAP-2 Inhibitoren
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
JP2014526545A (ja) 2014-10-06
CA2847921A1 (en) 2013-04-04
EP2760841B1 (en) 2016-08-24
JP6073328B2 (ja) 2017-02-01
SG11201400403SA (en) 2014-08-28
EP2573073A1 (en) 2013-03-27
EP2573073B1 (en) 2014-10-22
ES2527188T3 (es) 2015-01-21
HK1181763A1 (en) 2013-11-15
EP2760841A1 (en) 2014-08-06
PT2573073E (pt) 2015-02-05
MX2014003675A (es) 2014-08-21
SI2573073T1 (sl) 2015-02-27
PL2573073T3 (pl) 2015-04-30
CN103958479A (zh) 2014-07-30
CN103958479B (zh) 2017-06-13
HRP20150024T1 (hr) 2015-02-13
BR112014007193A2 (pt) 2017-04-04
TW201313719A (zh) 2013-04-01
IL231386A0 (en) 2014-04-30
RU2014117035A (ru) 2015-11-10
AU2012314620B2 (en) 2017-06-29
TWI527815B (zh) 2016-04-01
AU2012314620A1 (en) 2014-03-27
UY34350A (es) 2013-04-30
DK2573073T3 (en) 2015-01-19
RU2621037C2 (ru) 2017-05-31
AR088000A1 (es) 2014-04-30
WO2013045400A1 (en) 2013-04-04
KR20140082743A (ko) 2014-07-02
CY1115945T1 (el) 2017-01-25
IL231386A (en) 2016-04-21

Similar Documents

Publication Publication Date Title
ES2605152T3 (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico
PE20120629A1 (es) Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
PE20161475A1 (es) Pirazolopiridinas y pirazolopirimidinas
EA201001769A1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы
AR081072A1 (es) Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
UA108221C2 (uk) Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
JP2016530314A5 (es)
CY1110232T1 (el) Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
NO20090628L (no) Pyridizinon derivativater
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR088625A1 (es) Derivados de aril-quinolina
MX347562B (es) Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4.
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
TN2011000380A1 (en) Triazolopyridine derivatives as p38 map kinase inhibitors
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR081261A1 (es) Metodos para tratar afecciones virales
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer